{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Poorly+Differentiated+Thyroid+Cancer",
    "query": {
      "condition": "Metastatic Poorly Differentiated Thyroid Cancer"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 11,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Poorly+Differentiated+Thyroid+Cancer&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T02:12:50.799Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03896958",
      "title": "The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer, All Types",
        "Cancer of Liver",
        "Cancer of Stomach",
        "Cancer of Head and Neck",
        "Cancer of Rectum",
        "Cancer of Kidney",
        "Cancer of Esophagus",
        "Cancer of Colon",
        "Cancer Skin",
        "Cancer of Cervix",
        "Cancer, Metastatic",
        "Cancer of Larynx",
        "Cancer of Neck",
        "Cancer of Lung",
        "Cancer of Brain and Nervous System",
        "Cancer of Vulva, Disseminated",
        "Cancer of Pancreas",
        "Sarcoma",
        "GIST",
        "Small-cell Lung Cancer",
        "Adenocarcinoma Lung",
        "Cancer of Prostate",
        "Cancer, Advanced",
        "Adrenal Cancer",
        "Testicular Cancer",
        "Uterine Cancer",
        "Bronchoalveolar Cell Lung Cancer",
        "Cancer Unknown Primary",
        "Glioblastoma Multiforme",
        "Oligodendroglioma",
        "Breast Cancer",
        "Renal Cell Carcinoma",
        "Hepatocellular Carcinoma",
        "Cholangiocarcinoma",
        "Squamous Cell Carcinoma",
        "Transitional Cell Carcinoma",
        "Cancer, Other",
        "Cancer, Anal",
        "Melanoma",
        "Cancer, Bile Duct",
        "Cancer, Bladder",
        "Cancer Cords Vocal",
        "Cancers Cell Neuroendocrine",
        "Cancer Differentiated Poorly",
        "Cancer, Anaplastic Thyroid"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "SpeciCare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "1 Month to 99 Years"
      },
      "enrollment_count": 1000,
      "start_date": "2019-03-21",
      "completion_date": "2024-03-12",
      "has_results": false,
      "last_update_posted_date": "2020-12-04",
      "last_synced_at": "2026-05-22T02:12:50.799Z",
      "location_count": 1,
      "location_summary": "Gainesville, Georgia",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03896958"
    },
    {
      "nct_id": "NCT02152995",
      "title": "Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Thyroid Gland Carcinoma",
        "Poorly Differentiated Thyroid Gland Carcinoma",
        "Recurrent Thyroid Gland Carcinoma",
        "Refractory Thyroid Gland Carcinoma",
        "Stage IV Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IV Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Iodine I 124",
          "type": "OTHER"
        },
        {
          "name": "Iodine I-131",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacodynamic Study",
          "type": "OTHER"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2014-08-14",
      "completion_date": "2027-02-05",
      "has_results": true,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-05-22T02:12:50.799Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02152995"
    },
    {
      "nct_id": "NCT00654238",
      "title": "Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Differentiated Thyroid Cancer",
        "Metastatic Poorly Differentiated Thyroid Cancer",
        "Metastatic Anaplastic Thyroid Cancer",
        "Metastatic Medullary Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2006-02",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2019-11-18",
      "last_synced_at": "2026-05-22T02:12:50.799Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00654238"
    },
    {
      "nct_id": "NCT04171622",
      "title": "Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Thyroid Gland Carcinoma",
        "Poorly Differentiated Thyroid Gland Carcinoma",
        "Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8",
        "Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8",
        "Thyroid Gland Squamous Cell Carcinoma",
        "Unresectable Thyroid Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2021-11-04",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-05-22T02:12:50.799Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04171622"
    },
    {
      "nct_id": "NCT01534897",
      "title": "Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Papillary Thyroid Carcinoma"
      ],
      "interventions": [
        {
          "name": "GSK2118436",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2012-07",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2017-03-15",
      "last_synced_at": "2026-05-22T02:12:50.799Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01534897"
    },
    {
      "nct_id": "NCT03181100",
      "title": "Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Thyroid Gland Carcinoma",
        "Poorly Differentiated Thyroid Gland Carcinoma",
        "Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8",
        "Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8",
        "Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8",
        "Thyroid Gland Anaplastic Carcinoma",
        "Unresectable Thyroid Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Vemurafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2017-07-27",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-05-22T02:12:50.799Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03181100"
    },
    {
      "nct_id": "NCT02973997",
      "title": "Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Columnar Cell Variant Thyroid Gland Papillary Carcinoma",
        "Follicular Variant Thyroid Gland Papillary Carcinoma",
        "Metastatic Thyroid Gland Follicular Carcinoma",
        "Metastatic Thyroid Gland Papillary Carcinoma",
        "Poorly Differentiated Thyroid Gland Carcinoma",
        "Recurrent Differentiated Thyroid Gland Carcinoma",
        "Recurrent Thyroid Gland Follicular Carcinoma",
        "Recurrent Thyroid Gland Papillary Carcinoma",
        "Stage III Differentiated Thyroid Gland Carcinoma AJCC v7",
        "Stage III Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage III Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IV Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IV Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7",
        "Tall Cell Variant Thyroid Gland Papillary Carcinoma",
        "Thyroid Gland Hurthle Cell Carcinoma",
        "Unresectable Differentiated Thyroid Gland Carcinoma",
        "Unresectable Thyroid Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Lenvatinib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Academic and Community Cancer Research United",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2018-02-07",
      "completion_date": "2023-10-08",
      "has_results": true,
      "last_update_posted_date": "2025-08-29",
      "last_synced_at": "2026-05-22T02:12:50.799Z",
      "location_count": 7,
      "location_summary": "Torrance, California • Aurora, Colorado • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02973997"
    },
    {
      "nct_id": "NCT02244463",
      "title": "A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anaplastic Thyroid Cancer",
        "Thyroid Cancer",
        "Differentiated Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "MLN0128",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2015-07",
      "completion_date": "2022-04-28",
      "has_results": true,
      "last_update_posted_date": "2024-01-12",
      "last_synced_at": "2026-05-22T02:12:50.799Z",
      "location_count": 3,
      "location_summary": "Newport Beach, California • Boston, Massachusetts • Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02244463"
    },
    {
      "nct_id": "NCT03002623",
      "title": "CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thyroid Neoplasms",
        "Poorly Differentiated and Undifferentiated Thyroid Cancer",
        "Differentiated Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "CUDC-907",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 7,
      "start_date": "2016-12-22",
      "completion_date": "2018-02-12",
      "has_results": true,
      "last_update_posted_date": "2018-12-21",
      "last_synced_at": "2026-05-22T02:12:50.799Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03002623"
    },
    {
      "nct_id": "NCT02393690",
      "title": "Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Thyroid Gland Carcinoma",
        "Poorly Differentiated Thyroid Gland Carcinoma",
        "Recurrent Thyroid Gland Carcinoma",
        "Stage IV Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IV Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Iodine I-131",
          "type": "RADIATION"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        },
        {
          "name": "Selumetinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Academic and Community Cancer Research United",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2015-05-04",
      "completion_date": "2023-12-31",
      "has_results": true,
      "last_update_posted_date": "2024-07-26",
      "last_synced_at": "2026-05-22T02:12:50.799Z",
      "location_count": 11,
      "location_summary": "La Jolla, California • Newport Beach, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02393690"
    }
  ]
}